Sight Sciences, Inc. SGHT
We take great care to ensure that the data presented and summarized in this overview for Sight Sciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SGHT
View all-
Kck Ltd. Tortola, D84.37MShares$14.3 Million21.26% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR3.13MShares$10.2 Million0.26% of portfolio
-
Black Rock Inc. New York, NY2.12MShares$6.94 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.7MShares$5.55 Million0.0% of portfolio
-
Prosight Management, LP Dallas, TX969KShares$3.17 Million0.83% of portfolio
-
B Group, Inc. Dallas, TX834KShares$2.73 Million1.71% of portfolio
-
Geode Capital Management, LLC Boston, MA802KShares$2.62 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny684KShares$2.24 Million0.0% of portfolio
-
Apollo Management Holdings, L.P. New York, NY672KShares$2.2 Million0.03% of portfolio
-
State Street Corp Boston, MA648KShares$2.12 Million0.0% of portfolio
Latest Institutional Activity in SGHT
Top Purchases
Top Sells
About SGHT
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Insider Transactions at SGHT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 19
2025
|
Alison Bauerlein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,066
-2.01%
|
$39,198
$3.48 P/Share
|
|
May 16
2025
|
Matthew Link Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,631
+0.79%
|
$19,893
$3.02 P/Share
|
|
May 16
2025
|
Manohar K. Raheja EVP, Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
12,767
+7.07%
|
$38,301
$3.02 P/Share
|
|
May 12
2025
|
Gerhard F Burbach |
BUY
Grant, award, or other acquisition
|
Direct |
74,766
+44.1%
|
-
|
|
Apr 02
2025
|
Matthew Link Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,042
-0.6%
|
$10,084
$2.31 P/Share
|
|
Apr 02
2025
|
Jeremy B. Hayden Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,395
-3.3%
|
$18,790
$2.31 P/Share
|
|
Apr 02
2025
|
Alison Bauerlein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
19,397
-2.9%
|
$38,794
$2.31 P/Share
|
|
Apr 01
2025
|
David Badawi Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
5,980
-0.32%
|
$11,960
$2.3 P/Share
|
|
Apr 01
2025
|
Paul Badawi President and CEO |
SELL
Open market or private sale
|
Direct |
24,174
-0.4%
|
$48,348
$2.3 P/Share
|
|
Mar 13
2025
|
Manohar K. Raheja EVP, Research & Development |
BUY
Open market or private purchase
|
Direct |
10,000
+6.06%
|
$20,000
$2.6 P/Share
|
|
Mar 12
2025
|
Manohar K. Raheja EVP, Research & Development |
BUY
Open market or private purchase
|
Direct |
10,000
+6.45%
|
$20,000
$2.73 P/Share
|
|
Mar 12
2025
|
Staffan Encrantz |
BUY
Other acquisition or disposition
|
Indirect |
243,000
+4.56%
|
$486,000
$2.77 P/Share
|
|
Mar 11
2025
|
Jeremy B. Hayden Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
139,785
+32.92%
|
-
|
|
Mar 11
2025
|
Alison Bauerlein Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
286,738
+30.0%
|
-
|
|
Mar 11
2025
|
Manohar K. Raheja EVP, Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+15.09%
|
-
|
|
Mar 11
2025
|
Matthew Link Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
172,043
+17.07%
|
-
|
|
Mar 11
2025
|
David Badawi Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
98,566
+5.08%
|
-
|
|
Mar 11
2025
|
Paul Badawi President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
358,423
+5.61%
|
-
|
|
Mar 11
2025
|
Staffan Encrantz |
BUY
Other acquisition or disposition
|
Indirect |
150,000
+3.0%
|
$300,000
$2.71 P/Share
|
|
Mar 10
2025
|
Staffan Encrantz |
BUY
Other acquisition or disposition
|
Indirect |
120,000
+2.49%
|
$240,000
$2.53 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.53M shares |
|---|---|
| Other acquisition or disposition | 513K shares |
| Open market or private purchase | 587K shares |
| Open market or private sale | 855K shares |
|---|---|
| Payment of exercise price or tax liability | 12K shares |